Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Quest PharmaTech Inc. (QPTFF), an Edmonton, Canada-based pharmaceutical firm, specializes in creating antibody-driven immunotherapeutic remedies primarily for various cancers. A cornerstone of its product pipeline is Mab AR 9.6, an advanced therapeutic candidate specifically designed to target truncated O-glycans on MUC16 for precise cancer treatment applications. The company's offerings further encompass Oregovomab, an anti-CA-125 antibody that has successfully completed Phase II clinical trials for the management of ovarian cancer. Beyond these specific agents, Quest PharmaTech is actively involved in the development, manufacturing, and commercialization of new immunotherapy products aimed at combating pancreatic cancer. The organization also diversifies its portfolio by utilizing proprietary transdermal delivery technologies to formulate products for dermatological conditions and wound healing. Additionally, it develops specialized skin-penetrating active molecules for use in both cosmetic and pharmaceutical goods. Rounding out its innovative efforts, Quest PharmaTech designs intricate combinatorial immunotherapies for cancer, employing monoclonal antibodies belonging to both immunoglobulin G and E classes.
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, of fair value on EV/E